An  ||| S:0 E:3 ||| DT
analysis  ||| S:3 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
safety  ||| S:15 E:22 ||| NN
data  ||| S:22 E:27 ||| NNS
from  ||| S:27 E:32 ||| IN
five  ||| S:32 E:37 ||| CD
phase  ||| S:37 E:43 ||| NN
III  ||| S:43 E:47 ||| NNP
clinical  ||| S:47 E:56 ||| JJ
trials  ||| S:56 E:63 ||| NNS
on  ||| S:63 E:66 ||| IN
the  ||| S:66 E:70 ||| DT
use  ||| S:70 E:74 ||| NN
of  ||| S:74 E:77 ||| IN
botulinum  ||| S:77 E:87 ||| JJ
neurotoxin  ||| S:87 E:98 ||| JJ
type  ||| S:98 E:103 ||| NN
A-ABO  ||| S:103 E:109 ||| NN
for  ||| S:109 E:113 ||| IN
the  ||| S:113 E:117 ||| DT
treatment  ||| S:117 E:127 ||| NN
of  ||| S:127 E:130 ||| IN
glabellar  ||| S:130 E:140 ||| JJ
lines  ||| S:140 E:146 ||| NNS
A  ||| S:146 E:148 ||| DT
new  ||| S:148 E:152 ||| JJ
formulation  ||| S:152 E:164 ||| NN
of  ||| S:164 E:167 ||| IN
a  ||| S:167 E:169 ||| DT
botulinum  ||| S:169 E:179 ||| JJ
neurotoxin  ||| S:179 E:190 ||| JJ
type  ||| S:190 E:195 ||| NN
A  ||| S:195 E:197 ||| DT
( ||| S:197 E:198 ||| -LRB-
BoNTA-ABO ||| S:198 E:207 ||| NNP
;  ||| S:207 E:209 ||| :
Dysport  ||| S:209 E:217 ||| NNP
[ ||| S:217 E:218 ||| -LRB-
abobotulinumtoxinA ||| S:218 E:236 ||| NNP
] ||| S:236 E:237 ||| -RRB-
;  ||| S:237 E:239 ||| :
Medicis  ||| S:239 E:247 ||| NNP
Aesthetics ||| S:247 E:257 ||| NNP
,  ||| S:257 E:259 ||| ,
Scottsdale ||| S:259 E:269 ||| NNP
,  ||| S:269 E:271 ||| ,
AZ ||| S:271 E:273 ||| NNP
)  ||| S:273 E:275 ||| -RRB-
was  ||| S:275 E:279 ||| VBD
recently  ||| S:279 E:288 ||| RB
approved  ||| S:288 E:297 ||| VBN
by  ||| S:297 E:300 ||| IN
the  ||| S:300 E:304 ||| DT
US  ||| S:304 E:307 ||| NNP
Food  ||| S:307 E:312 ||| NNP
and  ||| S:312 E:316 ||| CC
Drug  ||| S:316 E:321 ||| NNP
Administration  ||| S:321 E:336 ||| NNP
for  ||| S:336 E:340 ||| IN
the  ||| S:340 E:344 ||| DT
treatment  ||| S:344 E:354 ||| NN
of  ||| S:354 E:357 ||| IN
moderate  ||| S:357 E:366 ||| JJ
to  ||| S:366 E:369 ||| TO
severe  ||| S:369 E:376 ||| JJ
glabellar  ||| S:376 E:386 ||| JJ
lines ||| S:386 E:391 ||| NNS
.  ||| S:391 E:393 ||| .
This  ||| S:393 E:398 ||| DT
article  ||| S:398 E:406 ||| NN
summarizes  ||| S:406 E:417 ||| VBD
the  ||| S:417 E:421 ||| DT
safety  ||| S:421 E:428 ||| NN
data  ||| S:428 E:433 ||| NNS
from  ||| S:433 E:438 ||| IN
five  ||| S:438 E:443 ||| CD
phase  ||| S:443 E:449 ||| NN
III  ||| S:449 E:453 ||| NNP
clinical  ||| S:453 E:462 ||| JJ
trials  ||| S:462 E:469 ||| NNS
investigating  ||| S:469 E:483 ||| VBG
the  ||| S:483 E:487 ||| DT
use  ||| S:487 E:491 ||| NN
of  ||| S:491 E:494 ||| IN
BoNTA-ABO  ||| S:494 E:504 ||| JJ
in  ||| S:504 E:507 ||| IN
the  ||| S:507 E:511 ||| DT
treatment  ||| S:511 E:521 ||| NN
of  ||| S:521 E:524 ||| IN
glabellar  ||| S:524 E:534 ||| JJ
lines ||| S:534 E:539 ||| NNS
.  ||| S:539 E:541 ||| .
Of  ||| S:541 E:544 ||| IN
the  ||| S:544 E:548 ||| DT
five  ||| S:548 E:553 ||| CD
phase  ||| S:553 E:559 ||| NN
III  ||| S:559 E:563 ||| NNP
studies  ||| S:563 E:571 ||| NNS
conducted ||| S:571 E:580 ||| VBN
,  ||| S:580 E:582 ||| ,
three  ||| S:582 E:588 ||| CD
were  ||| S:588 E:593 ||| VBD
multicenter ||| S:593 E:604 ||| CD
,  ||| S:604 E:606 ||| ,
randomized ||| S:606 E:616 ||| NN
,  ||| S:616 E:618 ||| ,
placebo-controlled ||| S:618 E:636 ||| NNP
,  ||| S:636 E:638 ||| ,
double-blind  ||| S:638 E:651 ||| JJ
studies  ||| S:651 E:659 ||| NNS
and  ||| S:659 E:663 ||| CC
two  ||| S:663 E:667 ||| CD
were  ||| S:667 E:672 ||| VBD
multicenter ||| S:672 E:683 ||| CD
,  ||| S:683 E:685 ||| ,
open-label ||| S:685 E:695 ||| NNP
,  ||| S:695 E:697 ||| ,
repeat-dose  ||| S:697 E:709 ||| JJ
studies  ||| S:709 E:717 ||| NNS
( ||| S:717 E:718 ||| -LRB-
one  ||| S:718 E:722 ||| CD
of  ||| S:722 E:725 ||| IN
which  ||| S:725 E:731 ||| WDT
was  ||| S:731 E:735 ||| VBD
an  ||| S:735 E:738 ||| DT
extension  ||| S:738 E:748 ||| NN
trial ||| S:748 E:753 ||| NN
) ||| S:753 E:754 ||| -RRB-
.  ||| S:754 E:756 ||| .
Two  ||| S:756 E:760 ||| CD
fixed-dose ||| S:760 E:770 ||| NN
,  ||| S:770 E:772 ||| ,
placebo-controlled  ||| S:772 E:791 ||| JJ
studies  ||| S:791 E:799 ||| NNS
randomized  ||| S:799 E:810 ||| VBP
a  ||| S:810 E:812 ||| DT
total  ||| S:812 E:818 ||| NN
of  ||| S:818 E:821 ||| IN
416  ||| S:821 E:825 ||| CD
patients  ||| S:825 E:834 ||| NNS
to  ||| S:834 E:837 ||| TO
receive  ||| S:837 E:845 ||| VB
one  ||| S:845 E:849 ||| CD
50-unit  ||| S:849 E:857 ||| CD
dose  ||| S:857 E:862 ||| NN
of  ||| S:862 E:865 ||| IN
BoNTA-ABO ||| S:865 E:874 ||| JJ
.  ||| S:874 E:876 ||| .
The  ||| S:876 E:880 ||| DT
single  ||| S:880 E:887 ||| JJ
variable-dose  ||| S:887 E:901 ||| JJ
study  ||| S:901 E:907 ||| NN
randomized  ||| S:907 E:918 ||| VBD
544  ||| S:918 E:922 ||| CD
patients  ||| S:922 E:931 ||| NNS
to  ||| S:931 E:934 ||| TO
receive  ||| S:934 E:942 ||| VB
50  ||| S:942 E:945 ||| CD
to  ||| S:945 E:948 ||| TO
80  ||| S:948 E:951 ||| CD
units  ||| S:951 E:957 ||| NNS
of  ||| S:957 E:960 ||| IN
BoNTA-ABO ||| S:960 E:969 ||| NNP
,  ||| S:969 E:971 ||| ,
as  ||| S:971 E:974 ||| RB
determined  ||| S:974 E:985 ||| VBN
by  ||| S:985 E:988 ||| IN
gender  ||| S:988 E:995 ||| NN
and  ||| S:995 E:999 ||| CC
patient  ||| S:999 E:1007 ||| JJ
muscle  ||| S:1007 E:1014 ||| NN
mass ||| S:1014 E:1018 ||| NN
.  ||| S:1018 E:1020 ||| .
A  ||| S:1020 E:1022 ||| DT
substudy  ||| S:1022 E:1031 ||| NN
of  ||| S:1031 E:1034 ||| IN
this  ||| S:1034 E:1039 ||| DT
variable-dose  ||| S:1039 E:1053 ||| JJ
study  ||| S:1053 E:1059 ||| NN
on  ||| S:1059 E:1062 ||| IN
QT ||| S:1062 E:1064 ||| NNP
/ ||| S:1064 E:1065 ||| NNP
QTc  ||| S:1065 E:1069 ||| JJ
prolongation  ||| S:1069 E:1082 ||| NN
included  ||| S:1082 E:1091 ||| VBD
50  ||| S:1091 E:1094 ||| CD
patients  ||| S:1094 E:1103 ||| NNS
randomized  ||| S:1103 E:1114 ||| VBP
to  ||| S:1114 E:1117 ||| TO
BoNTA-ABO ||| S:1117 E:1126 ||| JJ
.  ||| S:1126 E:1128 ||| .
One  ||| S:1128 E:1132 ||| CD
open-label  ||| S:1132 E:1143 ||| JJ
repeat-dose  ||| S:1143 E:1155 ||| JJ
study  ||| S:1155 E:1161 ||| NN
administered  ||| S:1161 E:1174 ||| VBN
50  ||| S:1174 E:1177 ||| CD
units  ||| S:1177 E:1183 ||| NNS
of  ||| S:1183 E:1186 ||| IN
BoNTA-ABO  ||| S:1186 E:1196 ||| JJ
to  ||| S:1196 E:1199 ||| TO
1200  ||| S:1199 E:1204 ||| CD
patients ||| S:1204 E:1212 ||| NNS
.  ||| S:1212 E:1214 ||| .
The  ||| S:1214 E:1218 ||| DT
single  ||| S:1218 E:1225 ||| JJ
extension  ||| S:1225 E:1235 ||| NN
study  ||| S:1235 E:1241 ||| NN
( ||| S:1241 E:1242 ||| -LRB-
N  ||| S:1242 E:1244 ||| NNP
=  ||| S:1244 E:1246 ||| SYM
1415 ||| S:1246 E:1250 ||| CD
)  ||| S:1250 E:1252 ||| -RRB-
included  ||| S:1252 E:1261 ||| VBD
both  ||| S:1261 E:1266 ||| DT
fixed  ||| S:1266 E:1272 ||| JJ
( ||| S:1272 E:1273 ||| -LRB-
5423  ||| S:1273 E:1278 ||| CD
treatments ||| S:1278 E:1288 ||| NNS
)  ||| S:1288 E:1290 ||| -RRB-
and  ||| S:1290 E:1294 ||| CC
variable  ||| S:1294 E:1303 ||| JJ
dosing  ||| S:1303 E:1310 ||| NNS
( ||| S:1310 E:1311 ||| -LRB-
1337  ||| S:1311 E:1316 ||| CD
treatments ||| S:1316 E:1326 ||| NNS
)  ||| S:1326 E:1328 ||| -RRB-
following  ||| S:1328 E:1338 ||| VBG
a  ||| S:1338 E:1340 ||| DT
protocol  ||| S:1340 E:1349 ||| NN
amendment ||| S:1349 E:1358 ||| NN
.  ||| S:1358 E:1360 ||| .
The  ||| S:1360 E:1364 ||| DT
extension  ||| S:1364 E:1374 ||| NN
study  ||| S:1374 E:1380 ||| NN
included  ||| S:1380 E:1389 ||| VBD
patients  ||| S:1389 E:1398 ||| NNS
from  ||| S:1398 E:1403 ||| IN
the  ||| S:1403 E:1407 ||| DT
four  ||| S:1407 E:1412 ||| CD
previously  ||| S:1412 E:1423 ||| RB
mentioned  ||| S:1423 E:1433 ||| VBN
studies ||| S:1433 E:1440 ||| NNS
.  ||| S:1440 E:1442 ||| .
Safety  ||| S:1442 E:1449 ||| NN
endpoints  ||| S:1449 E:1459 ||| NNS
were  ||| S:1459 E:1464 ||| VBD
adverse  ||| S:1464 E:1472 ||| JJ
events  ||| S:1472 E:1479 ||| NNS
( ||| S:1479 E:1480 ||| -LRB-
AE ||| S:1480 E:1482 ||| NNP
) ||| S:1482 E:1483 ||| -RRB-
,  ||| S:1483 E:1485 ||| ,
laboratory  ||| S:1485 E:1496 ||| NN
data ||| S:1496 E:1500 ||| NNS
,  ||| S:1500 E:1502 ||| ,
and  ||| S:1502 E:1506 ||| CC
changes  ||| S:1506 E:1514 ||| NNS
in  ||| S:1514 E:1517 ||| IN
vital  ||| S:1517 E:1523 ||| JJ
signs ||| S:1523 E:1528 ||| NNS
.  ||| S:1528 E:1530 ||| .
Of  ||| S:1530 E:1533 ||| IN
2485  ||| S:1533 E:1538 ||| CD
healthy  ||| S:1538 E:1546 ||| JJ
adult  ||| S:1546 E:1552 ||| NN
patients  ||| S:1552 E:1561 ||| NNS
with  ||| S:1561 E:1566 ||| IN
moderate  ||| S:1566 E:1575 ||| JJ
to  ||| S:1575 E:1578 ||| TO
severe  ||| S:1578 E:1585 ||| JJ
glabellar  ||| S:1585 E:1595 ||| JJ
lines  ||| S:1595 E:1601 ||| NNS
enrolled  ||| S:1601 E:1610 ||| VBD
in  ||| S:1610 E:1613 ||| IN
the  ||| S:1613 E:1617 ||| DT
trials ||| S:1617 E:1623 ||| NNS
,  ||| S:1623 E:1625 ||| ,
2160  ||| S:1625 E:1630 ||| CD
received  ||| S:1630 E:1639 ||| VBN
at  ||| S:1639 E:1642 ||| IN
least  ||| S:1642 E:1648 ||| JJS
one  ||| S:1648 E:1652 ||| CD
cycle  ||| S:1652 E:1658 ||| NN
of  ||| S:1658 E:1661 ||| IN
BoNTA-ABO ||| S:1661 E:1670 ||| JJ
.  ||| S:1670 E:1672 ||| .
Treatment  ||| S:1672 E:1682 ||| NN
of  ||| S:1682 E:1685 ||| IN
glabellar  ||| S:1685 E:1695 ||| JJ
lines  ||| S:1695 E:1701 ||| NNS
with  ||| S:1701 E:1706 ||| IN
50  ||| S:1706 E:1709 ||| CD
units  ||| S:1709 E:1715 ||| NNS
of  ||| S:1715 E:1718 ||| IN
BoNTA-ABO  ||| S:1718 E:1728 ||| NNP
was  ||| S:1728 E:1732 ||| VBD
well  ||| S:1732 E:1737 ||| RB
tolerated ||| S:1737 E:1746 ||| JJ
,  ||| S:1746 E:1748 ||| ,
with  ||| S:1748 E:1753 ||| IN
similar  ||| S:1753 E:1761 ||| JJ
rates  ||| S:1761 E:1767 ||| NNS
of  ||| S:1767 E:1770 ||| IN
treatment-emergent  ||| S:1770 E:1789 ||| JJ
adverse  ||| S:1789 E:1797 ||| JJ
events  ||| S:1797 E:1804 ||| NNS
( ||| S:1804 E:1805 ||| -LRB-
TEAE ||| S:1805 E:1809 ||| NNP
)  ||| S:1809 E:1811 ||| -RRB-
observed  ||| S:1811 E:1820 ||| VBD
in  ||| S:1820 E:1823 ||| IN
the  ||| S:1823 E:1827 ||| DT
active  ||| S:1827 E:1834 ||| JJ
treatment  ||| S:1834 E:1844 ||| NN
and  ||| S:1844 E:1848 ||| CC
placebo  ||| S:1848 E:1856 ||| JJ
groups  ||| S:1856 E:1863 ||| NNS
in  ||| S:1863 E:1866 ||| IN
terms  ||| S:1866 E:1872 ||| NNS
of  ||| S:1872 E:1875 ||| IN
type ||| S:1875 E:1879 ||| NN
,  ||| S:1879 E:1881 ||| ,
frequency ||| S:1881 E:1890 ||| NN
,  ||| S:1890 E:1892 ||| ,
severity ||| S:1892 E:1900 ||| NN
,  ||| S:1900 E:1902 ||| ,
and  ||| S:1902 E:1906 ||| CC
relatedness-with  ||| S:1906 E:1923 ||| JJ
the  ||| S:1923 E:1927 ||| DT
exception  ||| S:1927 E:1937 ||| NN
of  ||| S:1937 E:1940 ||| IN
injection  ||| S:1940 E:1950 ||| NN
site  ||| S:1950 E:1955 ||| NN
reactions  ||| S:1955 E:1965 ||| NNS
and  ||| S:1965 E:1969 ||| CC
ptosis ||| S:1969 E:1975 ||| NN
.  ||| S:1975 E:1977 ||| .
In  ||| S:1977 E:1980 ||| IN
the  ||| S:1980 E:1984 ||| DT
variable-dose ||| S:1984 E:1997 ||| JJ
,  ||| S:1997 E:1999 ||| ,
single-treatment  ||| S:1999 E:2016 ||| JJ
study ||| S:2016 E:2021 ||| NN
,  ||| S:2021 E:2023 ||| ,
BoNTA-ABO  ||| S:2023 E:2033 ||| NNP
was  ||| S:2033 E:2037 ||| VBD
well  ||| S:2037 E:2042 ||| RB
tolerated ||| S:2042 E:2051 ||| JJ
,  ||| S:2051 E:2053 ||| ,
with  ||| S:2053 E:2058 ||| IN
an  ||| S:2058 E:2061 ||| DT
incidence  ||| S:2061 E:2071 ||| NN
of  ||| S:2071 E:2074 ||| IN
active  ||| S:2074 E:2081 ||| JJ
TEAE  ||| S:2081 E:2086 ||| NNP
( ||| S:2086 E:2087 ||| -LRB-
31 ||| S:2087 E:2089 ||| CD
% ||| S:2089 E:2090 ||| NN
)  ||| S:2090 E:2092 ||| -RRB-
only  ||| S:2092 E:2097 ||| RB
slightly  ||| S:2097 E:2106 ||| RB
greater  ||| S:2106 E:2114 ||| JJR
than  ||| S:2114 E:2119 ||| IN
that  ||| S:2119 E:2124 ||| WDT
observed  ||| S:2124 E:2133 ||| VBD
for  ||| S:2133 E:2137 ||| IN
placebo  ||| S:2137 E:2145 ||| NNS
( ||| S:2145 E:2146 ||| -LRB-
28 ||| S:2146 E:2148 ||| CD
% ||| S:2148 E:2149 ||| NN
) ||| S:2149 E:2150 ||| -RRB-
.  ||| S:2150 E:2152 ||| .
In  ||| S:2152 E:2155 ||| IN
the  ||| S:2155 E:2159 ||| DT
repeat-dose  ||| S:2159 E:2171 ||| JJ
studies ||| S:2171 E:2178 ||| NNS
,  ||| S:2178 E:2180 ||| ,
there  ||| S:2180 E:2186 ||| EX
was  ||| S:2186 E:2190 ||| VBD
no  ||| S:2190 E:2193 ||| DT
evidence  ||| S:2193 E:2202 ||| NN
of  ||| S:2202 E:2205 ||| IN
cumulative  ||| S:2205 E:2216 ||| JJ
safety  ||| S:2216 E:2223 ||| NN
issues ||| S:2223 E:2229 ||| NNS
,  ||| S:2229 E:2231 ||| ,
the  ||| S:2231 E:2235 ||| DT
incidence  ||| S:2235 E:2245 ||| NN
of  ||| S:2245 E:2248 ||| IN
TEAE  ||| S:2248 E:2253 ||| NNP
decreased  ||| S:2253 E:2263 ||| VBD
over  ||| S:2263 E:2268 ||| IN
time ||| S:2268 E:2272 ||| NN
,  ||| S:2272 E:2274 ||| ,
and  ||| S:2274 E:2278 ||| CC
patients  ||| S:2278 E:2287 ||| NNS
did  ||| S:2287 E:2291 ||| VBD
not  ||| S:2291 E:2295 ||| RB
drop  ||| S:2295 E:2300 ||| VB
out  ||| S:2300 E:2304 ||| RP
because  ||| S:2304 E:2312 ||| IN
of  ||| S:2312 E:2315 ||| IN
TEAE ||| S:2315 E:2319 ||| NNP
.  ||| S:2319 E:2321 ||| .
The  ||| S:2321 E:2325 ||| DT
most  ||| S:2325 E:2330 ||| RBS
frequently  ||| S:2330 E:2341 ||| RB
reported  ||| S:2341 E:2350 ||| VBD
AE  ||| S:2350 E:2353 ||| NNP
were  ||| S:2353 E:2358 ||| VBD
nasopharyngitis ||| S:2358 E:2373 ||| CD
,  ||| S:2373 E:2375 ||| ,
sinusitis ||| S:2375 E:2384 ||| NN
,  ||| S:2384 E:2386 ||| ,
upper  ||| S:2386 E:2392 ||| JJ
respiratory  ||| S:2392 E:2404 ||| JJ
tract  ||| S:2404 E:2410 ||| NN
infection ||| S:2410 E:2419 ||| NN
,  ||| S:2419 E:2421 ||| ,
headache ||| S:2421 E:2429 ||| NN
,  ||| S:2429 E:2431 ||| ,
and  ||| S:2431 E:2435 ||| CC
injection  ||| S:2435 E:2445 ||| NN
site  ||| S:2445 E:2450 ||| NN
reactions ||| S:2450 E:2459 ||| NNS
.  ||| S:2459 E:2461 ||| .
The  ||| S:2461 E:2465 ||| DT
majority  ||| S:2465 E:2474 ||| NN
of  ||| S:2474 E:2477 ||| IN
TEAE  ||| S:2477 E:2482 ||| NNP
were  ||| S:2482 E:2487 ||| VBD
considered  ||| S:2487 E:2498 ||| VBN
unlikely  ||| S:2498 E:2507 ||| JJ
to  ||| S:2507 E:2510 ||| TO
be  ||| S:2510 E:2513 ||| VB
related  ||| S:2513 E:2521 ||| VBN
or  ||| S:2521 E:2524 ||| CC
were  ||| S:2524 E:2529 ||| VBD
not  ||| S:2529 E:2533 ||| RB
related  ||| S:2533 E:2541 ||| VBN
to  ||| S:2541 E:2544 ||| TO
BoNTA-ABO  ||| S:2544 E:2554 ||| JJ
treatment ||| S:2554 E:2563 ||| NN
.  ||| S:2563 E:2565 ||| .
In  ||| S:2565 E:2568 ||| IN
all  ||| S:2568 E:2572 ||| DT
studies ||| S:2572 E:2579 ||| NNS
,  ||| S:2579 E:2581 ||| ,
the  ||| S:2581 E:2585 ||| DT
TEAE  ||| S:2585 E:2590 ||| NN
that  ||| S:2590 E:2595 ||| WDT
were  ||| S:2595 E:2600 ||| VBD
considered  ||| S:2600 E:2611 ||| VBN
possibly  ||| S:2611 E:2620 ||| RB
related  ||| S:2620 E:2628 ||| VBN
to  ||| S:2628 E:2631 ||| TO
treatment  ||| S:2631 E:2641 ||| NN
were  ||| S:2641 E:2646 ||| VBD
primarily  ||| S:2646 E:2656 ||| RB
headaches  ||| S:2656 E:2666 ||| NNS
( ||| S:2666 E:2667 ||| -LRB-
with  ||| S:2667 E:2672 ||| IN
rates  ||| S:2672 E:2678 ||| NNS
comparable  ||| S:2678 E:2689 ||| JJ
to  ||| S:2689 E:2692 ||| TO
those  ||| S:2692 E:2698 ||| DT
observed  ||| S:2698 E:2707 ||| NN
for  ||| S:2707 E:2711 ||| IN
placebo ||| S:2711 E:2718 ||| CD
) ||| S:2718 E:2719 ||| -RRB-
,  ||| S:2719 E:2721 ||| ,
injection  ||| S:2721 E:2731 ||| NN
site  ||| S:2731 E:2736 ||| NN
reactions ||| S:2736 E:2745 ||| NNS
,  ||| S:2745 E:2747 ||| ,
and  ||| S:2747 E:2751 ||| CC
eye  ||| S:2751 E:2755 ||| NN
disorders  ||| S:2755 E:2765 ||| NNS
( ||| S:2765 E:2766 ||| -LRB-
such  ||| S:2766 E:2771 ||| JJ
as  ||| S:2771 E:2774 ||| IN
blepharospasm  ||| S:2774 E:2788 ||| NN
and  ||| S:2788 E:2792 ||| CC
eyelid  ||| S:2792 E:2799 ||| JJ
ptosis ||| S:2799 E:2805 ||| NN
) ||| S:2805 E:2806 ||| -RRB-
.  ||| S:2806 E:2808 ||| .
There  ||| S:2808 E:2814 ||| EX
were  ||| S:2814 E:2819 ||| VBD
no  ||| S:2819 E:2822 ||| DT
clinically  ||| S:2822 E:2833 ||| JJ
significant  ||| S:2833 E:2845 ||| JJ
changes  ||| S:2845 E:2853 ||| NNS
in  ||| S:2853 E:2856 ||| IN
hematologic  ||| S:2856 E:2868 ||| NN
or  ||| S:2868 E:2871 ||| CC
biochemical  ||| S:2871 E:2883 ||| JJ
parameters  ||| S:2883 E:2894 ||| NNS
or  ||| S:2894 E:2897 ||| CC
in  ||| S:2897 E:2900 ||| IN
vital  ||| S:2900 E:2906 ||| JJ
signs ||| S:2906 E:2911 ||| NNS
.  ||| S:2911 E:2913 ||| .
The  ||| S:2913 E:2917 ||| DT
cardiovascular  ||| S:2917 E:2932 ||| JJ
substudy  ||| S:2932 E:2941 ||| NN
revealed  ||| S:2941 E:2950 ||| VBD
that  ||| S:2950 E:2955 ||| IN
BoNTA-ABO  ||| S:2955 E:2965 ||| NNP
had  ||| S:2965 E:2969 ||| VBD
no  ||| S:2969 E:2972 ||| DT
effect  ||| S:2972 E:2979 ||| NN
on  ||| S:2979 E:2982 ||| IN
QT ||| S:2982 E:2984 ||| NNP
/ ||| S:2984 E:2985 ||| NNP
QTc  ||| S:2985 E:2989 ||| JJ
prolongation ||| S:2989 E:3001 ||| NN
.  ||| S:3001 E:3003 ||| .
Treatment  ||| S:3003 E:3013 ||| NN
of  ||| S:3013 E:3016 ||| IN
glabellar  ||| S:3016 E:3026 ||| JJ
lines  ||| S:3026 E:3032 ||| NNS
with  ||| S:3032 E:3037 ||| IN
BoNTA-ABO  ||| S:3037 E:3047 ||| NNP
is  ||| S:3047 E:3050 ||| VBZ
well  ||| S:3050 E:3055 ||| RB
tolerated ||| S:3055 E:3064 ||| VBN
.  ||| S:3064 E:3066 ||| .
Overall ||| S:3066 E:3073 ||| RB
,  ||| S:3073 E:3075 ||| ,
the  ||| S:3075 E:3079 ||| DT
safety  ||| S:3079 E:3086 ||| NN
profile  ||| S:3086 E:3094 ||| NN
of  ||| S:3094 E:3097 ||| IN
BoNTA-ABO  ||| S:3097 E:3107 ||| NNP
is  ||| S:3107 E:3110 ||| VBZ
comparable  ||| S:3110 E:3121 ||| JJ
to  ||| S:3121 E:3124 ||| TO
that  ||| S:3124 E:3129 ||| DT
of  ||| S:3129 E:3132 ||| IN
placebo  ||| S:3132 E:3140 ||| NN
in  ||| S:3140 E:3143 ||| IN
terms  ||| S:3143 E:3149 ||| NNS
of  ||| S:3149 E:3152 ||| IN
type ||| S:3152 E:3156 ||| NN
,  ||| S:3156 E:3158 ||| ,
frequency ||| S:3158 E:3167 ||| NN
,  ||| S:3167 E:3169 ||| ,
severity ||| S:3169 E:3177 ||| NN
,  ||| S:3177 E:3179 ||| ,
and  ||| S:3179 E:3183 ||| CC
relatedness  ||| S:3183 E:3195 ||| NN
of  ||| S:3195 E:3198 ||| IN
AE ||| S:3198 E:3200 ||| NNP
.  ||| S:3200 E:3202 ||| .
